secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004159
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports preliminary cash balance of ~$438M as of Dec 31, 2022
---------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and short-term investments were approximately $438 million.
- Cash balance is subject to completion of financial closing and audit; actual results may differ.
- Company updated its corporate presentation materials (Exhibit 99.1), but substantive details not provided in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312523004159/0001193125-23-004159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312523004159/d446484d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer